GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2013

Acorda Wins $2.67M Army Contract for Spinal Cord Injury Drug Trial

  • Acorda Therapeutics said today it won a $2.67 million contract from the U.S. Army Medical Research and Material Command (USAMRMC) to support development of AC105 as a treatment for acute spinal cord injury (SCI).

    The contract will help fund a Phase II clinical trial designed primarily to assess the safety and tolerability of AC105 in patients with acute SCI. The company plans to open enrollment for this study in the first half of this year.

    AC105, a modified form of magnesium, has shown neuroprotective properties and improvement of locomotor function in SCI in preclinical studies, once therapy was initiated within several hours of injury. FDA has granted fast-track designation for AC105 to improve functional recovery of acute SCI patients.

    Acorda said in a statement that it expects to apply for FDA orphan drug designation for acute treatment of SCI, and will explore orphan drug designations in Europe and elsewhere in the world.

    Acorda licenses worldwide development and commercialization rights to AC105 from Medtronic, which carried out the drug candidate’s Phase I study. Under a 2011 agreement, Acorda paid Medtronic $3 million up-front, and agreed to pay up to $32 million tied to regulatory and development milestones. If Acorda successfully commercializes AC105, the company will also pay Medtronic a single-digit sales royalty.

    Acorda's rights are exclusive for indications of interest to the company—including SCI, traumatic brain injury, stroke, and all other traumatic and ischemic central nervous system indications. Medtronic and Acorda share nonexclusive development rights in other specific areas, including certain areas of pain and musculoskeletal indications.

    At the time, Acorda said it acquired rights to AC105 as a complement to its lead neuregulin drug candidate, Glial Growth factor 2 (GGF2), as well as to the company’s preclinical programs in remyelination and spinal cord injury. Acorda envisions AC105 for several nervous system and cardiac indications including heart failure, peripheral nerve damage, stroke, multiple sclerosis, and SCI.

    Last month, the company completed its first Phase I clinical trial of GGF2, which explored the drug’s safety and tolerability in heart failure patients.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »